SEARCH

SEARCH BY CITATION

Reference

  • 1
    Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol Rev 1996; 18: 17587.
  • 2
    Saw SM. How blinding is pathological myopia? Br J Ophthalmol 2006; 90: 5256.
  • 3
    Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing eye study. Ophthalmology 2010; 117: 17638.
  • 4
    Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai eye study. Ophthalmology 2004; 111: 629.
  • 5
    Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi study. Ophthalmology 2006; 113: 135462.
  • 6
    Van Newkirk MR. The Hong Kong vision study: a pilot assessment of visual impairment in adults. Trans Am Ophthalmol Soc 1997; 95: 71549.
  • 7
    Kempen JH, Mitchell P, Lee KE et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol 2004; 122: 495505.
  • 8
    Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam eye study. Invest Ophthalmol Vis Sci 1994; 35: 43447.
  • 9
    Tarczy-Hornoch K, Ying-Lai M, Varma R. Myopic refractive error in adult Latinos: the Los Angeles Latino eye study. Invest Ophthalmol Vis Sci 2006; 47: 184552.
  • 10
    Attebo K, Ivers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains eye study. Ophthalmology 1999; 106: 106672.
  • 11
    Cedrone C, Culasso F, Cesareo M et al. Incidence of blindness and low vision in a sample population: the Priverno eye study, Italy. Ophthalmology 2003; 110: 5848.
  • 12
    Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City eye study. Ophthalmology 2004; 111: 5361.
  • 13
    Riise R. Myopia as cause of blindness. Acta Ophthalmol Suppl 1988; 185: 10910.
  • 14
    Sperduto RD, Seigel D, Roberts J, Rowland M. Prevalence of myopia in the United States. Arch Ophthalmol 1983; 101: 4057.
  • 15
    Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992; 12: 12733.
  • 16
    Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 157381.
  • 17
    Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103: 12414.
  • 18
    Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 10626.
  • 19
    Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981; 91: 17783.
  • 20
    Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 9236.
  • 21
    Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial – VIP report no. 1. Ophthalmology 2001; 108: 84152.
  • 22
    Baba T, Ohno-Matsui K, Yoshida T et al. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand 2002; 80: 827.
  • 23
    Kobayashi K, Mandai M, Suzuma I, Kobayashi H, Okinami S. Expression of estrogen receptor in the choroidal neovascular membranes in highly myopic eyes. Retina 2002; 22: 41822.
  • 24
    Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 30716.
  • 25
    Tabandeh H, Flynn HW Jr, Scott IU et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106: 20637.
  • 26
    Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001; 24: 24955.
  • 27
    Yoshida T, Ohno-Matsui K, Ohtake Y et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002; 109: 7129.
  • 28
    Hayashi K, Ohno-Matsui K, Yoshida T et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005; 243: 139.
  • 29
    Yoshida T, Ohno-Matsui K, Yasuzumi K et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110: 1297305.
  • 30
    Kojima A, Ohno-Matsui K, Teramukai S et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006; 244: 14749.
  • 31
    Soubrane G, Pison J, Bornert P, Perrenoud F, Coscas G. [Subretinal neovessels in degenerative myopia: results of photocoagulation]. Bull Soc Ophtalmol Fr 1986; 86: 26972.
  • 32
    Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990; 10: 23943.
  • 33
    Pece A, Brancato R, Avanza P, Camesasca F, Galli L. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1994; 18: 33944.
  • 34
    Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002; 12: 11722.
  • 35
    Blinder KJ, Blumenkranz MS, Bressler NM et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003; 110: 66773.
  • 36
    Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004; 88: 13159.
  • 37
    Schnurrbusch UE, Jochmann C, Wiedemann P, Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2005; 243: 82933.
  • 38
    Pece A, Isola V, Vadala M, Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina 2006; 26: 74651.
  • 39
    Chen YS, Lin JY, Tseng SY, Yow SG, Hsu WJ, Tsai SC. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina 2007; 27: 83945.
  • 40
    Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92: 7924.
  • 41
    Axer-Siegel R, Ehrlich R, Yassur Y et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol 2004; 137: 25864.
  • 42
    Costa RA, Williams GA. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. Retina 2006; 26: 75764.
  • 43
    Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 1749.
  • 44
    Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006; 142: 3357.
  • 45
    Virgili G, Varano M, Giacomelli G et al. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol 2007; 143: 7782.
  • 46
    Pece A, Vadala M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007; 143: 44954.
  • 47
    Gibson J. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularisation secondary to pathological myopia. Eye (Lond) 2005; 19: 82930.
  • 48
    Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye (Lond) 2005; 19: 83440.
  • 49
    Gelisken F, Inhoffen W, Hermann A, Grisanti S, Bartz-Schmidt KU. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2004; 242: 92630.
  • 50
    Ohno-Matsui K, Yoshida T, Futagami S et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003; 87: 5703.
  • 51
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 66976.
  • 52
    Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 32835.
  • 53
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 19.
  • 54
    Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 103547.
  • 55
    Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 136870.
  • 56
    Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 25761.
  • 57
    Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 3369.
  • 58
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 3315.
  • 59
    Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 61425.
  • 60
    Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 15760.
  • 61
    Sakaguchi H, Ikuno Y, Gomi F et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 1615.
  • 62
    Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 9603.
  • 63
    Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114: 21906.
  • 64
    Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 70712.
  • 65
    Dithmar S, Schaal KB, Hoh AE, Schmidt S, Schutt F. [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia]. Ophthalmologe 2009; 106: 52730.
  • 66
    Rensch F, Spandau UH, Schlichtenbrede F et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008; 39: 1825.
  • 67
    Silva RM, Ruiz-Moreno JM, Nascimento J et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 111723.
  • 68
    Arias L, Planas N, Prades S et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008; 92: 10359.
  • 69
    Rheaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008; 43: 57680.
  • 70
    Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol 2009; 87: 4603.
  • 71
    Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A. Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 2008; 28: 4257.
  • 72
    Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007; 21: 1857.
  • 73
    Ruiz-Moreno JM, Montero JA, Arias L et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010; 30: 160915.
  • 74
    Ikuno Y, Sayanagi K, Soga K et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147: 94100. e1.
  • 75
    Ruiz-Moreno JM, Gomez-Ulla F, Montero JA et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (Lond) 2009; 23: 3348.
  • 76
    Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009; 93: 1504.
  • 77
    Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147: 8493. e1.
  • 78
    Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye (Lond) 2009; 23: 20425.
  • 79
    Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010; 248: 93741.
  • 80
    Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010; 248: 54350.
  • 81
    Nakanishi H, Tsujikawa A, Yodoi Y et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011; 25: 37581.
  • 82
    Ikuno Y, Nagai Y, Matsuda S et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149: 1406.
  • 83
    Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94: 86470.
  • 84
    Gharbiya M, Allievi F, Conflitti S et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161: e8793.
  • 85
    Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005; 140: 41625.
  • 86
    Yamashiro K, Tsujikawa A, Miyamoto K et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010; 30: 48590.
  • 87
    Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009; 93: 44851.
  • 88
    Hayashi K, Ohno-Matsui K, Teramukai S et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148: 396408.
  • 89
    Yodoi Y, Tsujikawa A, Nakanishi H et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009; 147: 81624. 24 e1.
  • 90
    Scupola A, Tiberti AC, Sasso P et al. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results. Retina 2010; 30: 73947.
  • 91
    Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 56683.
  • 92
    Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126: 5969.
  • 93
    Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina 2011; 31: 8806.
  • 94
    Ikuno Y, Soga K, Wakabayashi T, Gomi F. Angiographic changes after bevacizumab. Ophthalmology 2009; 116: 2263 e1.
  • 95
    Axer-Siegel R, Ehrlich R, Weinberger D et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004; 138: 6027.
  • 96
    Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004; 138: 4348.
  • 97
    Wong D, Li KK. Avastin in myopic choroidal neovascularisation: is age the limit? Br J Ophthalmol 2008; 92: 10112.
  • 98
    Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol 2009; 93: 16934.
  • 99
    Hayashi K, Ohno-Matsui K, Shimada N et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 60918.
  • 100
    Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004; 138: 8038.
  • 101
    Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128: 43742.
  • 102
    Mordenti J, Cuthbertson RA, Ferrara N et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 53644.
  • 103
    Silva RM, Ruiz-Moreno JM, Rosa P et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30: 40712.
  • 104
    Silva RM, Ruiz-Moreno JM, Nascimento J et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 111723.
  • 105
    Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 3118.
  • 106
    Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009; 23: 127580. quiz 81.
  • 107
    Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 7506.
  • 108
    Lalloum F, Souied EH, Bastuji-Garin S et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010; 30: 399406.
  • 109
    Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 2011; 151: 52934.
  • 110
    Vadala M, Pece A, Cipolla S et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 2010; 95: 65761.
  • 111
    Varano M, Tedeschi M, Oddone F, Perillo L, Coppe AM, Parravano M. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Retina 2010; 30: 4137.
  • 112
    Gharbiya M, Giustolisi R, Allievi F et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab – a randomized controlled trial. Am J Ophthalmol 2010; 149: 45864. e1.
  • 113
    Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30: 41824.
  • 114
    Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007; 245: 9035.